ScinoPharm chief exec Jo Shen to retire and be replaced by Yung-Fa Chen

11 July 2014

Taiwan-based pharmaceutical company ScinoPharm (TWSE: 1789) says that its president and chief executive will retire at the end of July after 17 years of service. He will be succeeded by Dr Yung-Fa (Fred) Chen, who is currently the company’s vice president of research and development, and chief technology officer, from August 1.

Dr Chen has held various management positions since joining ScinoPharm in 1998, and currently holds 10 patents.

Kao-Huei Cheng, chairman of ScinoPharm, said: "Dr. Chen has been a part of the senior management team for over 16 years, playing a key role in ScinoPharm's growth. His scientific breadth and experience in organization leadership will allow us to continually build on the firm API business foundation established thus far while expanding into the injectable and formulation sectors for vertical integration. The Board looks forward to him to lead the company in its next stage of growth."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK